Table 1

Binding of PE-labeled anti-HER-2 MAb, Herceptin, to cultured cells from ovarian carcinoma

FACS analysis was performed as stated in “Materials and Methods” with the data analyzed using Coulter software. The anti-CD20 MAb Rituxan was used as a control for Herceptin in experiments with tumor lines 3907, 3909, 3997, 4007, 4010, 4020, 42OV, and 50OV. Percentage binding was 0, 0, 4, 11, 10, 7, 11, and 8, respectively.
Tumor line designationSourceBinding of murine anti-HER-2 (% cells)Binding of MAb Herceptin (% cells)a
3538effusion9297
3633effusion9871
3639biopsy6771
3723effusion99NT
3729effusion99NT
3730effusion99 ± 1 (n = 3)89 ± 7 (n = 2)
3750effusion18NT
3907biopsy85 ± 15 (n = 2)84
3909effusion85 ± 15 (n = 2)56
3997effusion79 ± 19 (n = 2)96
4007effusion97 ± 1 (n = 2)99
4010effusion87 ± 10 (n = 2)92
4020biopsy95 ± 5 (n = 2)99
4021effusion36NT
4022effusion28NT
11OVeffusion7243
36OVeffusion51NT
37OVbiopsy14NT
42OVeffusion93 ± 7 (n = 2)90 ± 9 (n = 2)
50OVeffusion91 ± 5 (n = 2)78
OVCAR-3effusion95 ± 5 (n = 3)98 ± 2 (n = 3)
  • a NT, not tested.